Technical Analysis for FGEN - FibroGen, Inc

Grade Last Price % Change Price Change
grade D 52.98 -4.75% -2.64
FGEN closed down 4.75 percent on Friday, March 22, 2019, on 1.26 times normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical FGEN trend table...

Date Alert Name Type % Chg
Mar 22 Fell Below 200 DMA Bearish 0.00%
Mar 22 Fell Below 50 DMA Bearish 0.00%
Mar 22 MACD Bearish Centerline Cross Bearish 0.00%
Mar 22 Stochastic Reached Oversold Weakness 0.00%
Mar 22 Lower Bollinger Band Touch Weakness 0.00%
Mar 22 Oversold Stochastic Weakness 0.00%
Mar 21 50 DMA Support Bullish -4.75%
Mar 21 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -4.75%
Mar 20 50 DMA Support Bullish -3.81%
Mar 20 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -3.81%

Older signals for FGEN ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
FibroGen, Inc. operates as a research-based biopharmaceutical company in the United States. The company focuses on the discovery, development, and commercialization of therapeutic agents to treat serious unmet medical needs. The company develops roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; and FG-3019, a monoclonal antibody, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and liver fibrosis. It also focuses on use of the proprietary type III recombinant human collagens in its biosynthetic corneal implant product candidate, FG-5200 for the treatment of corneal blindness. The company was incorporated in 1993 and is headquartered in San Francisco, California.
Biotechnology Biopharmaceutical Life Sciences Chronic Kidney Disease Pancreatic Cancer Anemia Idiopathic Pulmonary Fibrosis Hypoxia Inducible Factors Liver Fibrosis Research Based Biopharmaceutical
Is FGEN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 68.55
52 Week Low 37.27
Average Volume 616,521
200-Day Moving Average 54.2065
50-Day Moving Average 55.2532
20-Day Moving Average 56.3915
10-Day Moving Average 55.398
Average True Range 2.0866
ADX 18.5
+DI 16.0006
-DI 22.0551
Chandelier Exit (Long, 3 ATRs ) 54.9702
Chandelier Exit (Short, 3 ATRs ) 58.9398
Upper Bollinger Band 59.8924
Lower Bollinger Band 52.8906
Percent B (%b) 0.01
BandWidth 12.41641
MACD Line -0.185
MACD Signal Line 0.2404
MACD Histogram -0.4254
Fundamentals Value
Market Cap 3.77 Billion
Num Shares 71.2 Million
EPS -1.92
Price-to-Earnings (P/E) Ratio -27.59
Price-to-Sales 32.73
Price-to-Book 16.72
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 57.06
Resistance 3 (R3) 57.41 56.41 56.38
Resistance 2 (R2) 56.41 55.37 56.23 56.15
Resistance 1 (R1) 54.69 54.73 54.19 54.34 55.93
Pivot Point 53.69 53.69 53.44 53.51 53.69
Support 1 (S1) 51.97 52.65 51.47 51.62 50.03
Support 2 (S2) 50.97 52.01 50.79 49.81
Support 3 (S3) 49.25 50.97 49.58
Support 4 (S4) 48.90